Well it's absolutely pouring here in the city and my wife didn't think it amazing enough to be on an island- Nantucket she is on a smaller island nearby and took a boat to get there... I swear.
Ok so we have RocketLab... BlackSky, BLDE mobility here is number 4 //// Genius Sports Scores an 18-Month High on NFL Deal - Tue Jul 11, 6:03AM CDT Sports technology player Genius Sports Limited (NYSE: GENI) is mounting quite the comeback. A year removed from a crushing 10-month losing streak, shares of the London-based company have surged 186% over the last 12 months amid a relentless pursuit of professional sports partnerships. Another former SPAC rejuvenated in recent weeks, Genius Sports gained serious yardage late last week after extending its contract with the National Football League (NFL). The revised deal will see Genius Sports power the next-gen NFL fan experience through the 2027-2028 season by distributing real-time league data and video to sportsbooks and media outlets. The company is already the exclusive distributor of NFL play-by-play statistics, Next Gen Stats and the league’s official sports betting data feed. Under the terms of the updated agreement, Genius Sports will also be able to distribute digital advertising, official NFL marks and team logos, and NFL ‘Watch & Bet’ live game video feeds in international markets. Starting this season, NFL Watch & Bet games will be distributed to sportsbooks in the U.S. and Canada using machine learning and live stream technologies developed by Genius Sports. The three-year extension comes at a time when the NFL is dealing with player suspensions for violating league gambling policies. Genius Sports also monitors suspicious NFL betting activity and will continue to provide a 24/7 bet monitoring service. What Does This Mean for Genius Sports’ Financials? When it first struck a deal with Genius Sports in 2021, the NFL’s asking price for data rights was reported to be $100 million annually — and the finalized deal was assumed to be worth as much as $1 billion. To gain access to the rights, Genius Sports awarded warrants to the NFL that have made the league an 8% stakeholder. It's unknown how much Genius Sports is making on its NFL deal. The company generates revenue from “In-Play betting” and “Handle” tied to sportsbook betting activity. Since the multi-year NFL extension involves not just time but new products and services, it should lead to a significantly higher sportsbook revenue share. In the first quarter of 2023, Genius Sports grew its revenue 25% year-over-year to $105 million but posted a much wider net loss of $128 million. The results highlighted the market’s struggle with reconciling strong top line growth and escalating costs. The NFL extension undoubtedly comes at a high price, including the potential loss of additional equity rights, but it was a must-have. Genius Sports simply couldn’t afford to lose the NFL to a competitor like Sportradar, which already owns deals with the NBA, NHL and MLB. **--> I would bet they are getting a terrible deal from NFL! that's why they got the contract and not Sportrader<-- which is a more pulled together company.
Very interesting chart here--- it's funny some charts you look one moment and see one thing and the next another.// I see a big ole' bowel base and something starting to happen.. but the slope is gradual.. beautiful but gradual.... take a look- https://seekingalpha.com/symbol/ROI...rval=1M&metric=diluted_eps_growth,totalReturn
Prob not an accurate AH read but next week we should follow- Quantum-Si incorporated (QSI) NasdaqGM - NasdaqGM Real Time Price. 2.4200-0.1600 (-6.20%) At close: July 14 04:00PM EDT 2.6700 +0.25 (+10.33%) After hours: Jul 14, 07:59PM EDT
June 22 surprising the stk did not get higher than $10.87: Roivant Sciences This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission1 (36% at week 56 vs. 29% at week 14) and Endoscopic Improvement2 (50% vs. 36%) At the expected Phase 3 once-monthly subcutaneous dose in the biomarker positive population, RVT-3101 treatment resulted in improved Clinical Remission (43% at week 56 vs. 33% at week 14) and Endoscopic Improvement (64% vs. 47%) Across all patients dosed in the chronic period, RVT-3101 treatment produced clinically meaningful efficacy results, which improved between the induction and chronic period across multiple endpoints Across all doses and patient groups, RVT-3101 was well tolerated and showed a favorable safety profile There was no negative impact of antidrug antibodies (ADAs) on short-term or long-term efficacy results of RVT-3101 across all patients treated, and 0% of patients had neutralizing antibodies (NAbs) at week 56 at the expected Phase 3 dose TUSCANY-2 is among the largest Phase 2b studies conducted in moderate to severe ulcerative colitis with 245 patients treated Roivant will host a conference call to discuss results at 8 a.m. EDT on Thursday, June 22, 2023
Roivant Sciences Ltd. (ROIV)<-- On watch! NasdaqGM - NasdaqGM Real Time Price. 11.67+0.07 (+0.60%) At close: July 14 04:00PM EDT 11.90 +0.23 (+1.97%) After hours: Jul 14, 07:58PM EDT